Here are the AUA 2015 take-home messages on sexual/dysfunction, presented by Landon Trost, MD.
Erectile Dysfunction Treatment and Diagnosis
Use of testosterone replacement therapy more than tripled between 2003 and 2012 in a population of reproductive-age men, according to a study presented at the AUA annual meeting in New Orleans.
“The FDA is being very cautious, which as the protector of public health, it’s got to be," says one urologist.
Other products featured include: Radiosurgery collimator allows treatment of broad rang of tumors and Phi prostate cancer test and more.
In this first installment of UrologyTimes.com's new video section, called ‘Y’tube, we present videos from high-volume prosthetic surgeons performing inflatable penile prosthesis (IPP) placement and discussing diagnosis and management of ED. William O. Brant, MD, offers the following general commentary about these procedures, as well as specific comments in the text accompanying each individual video.
Landon Trost, MD, presents the take home messages on sexual function/dysfunction from the AUA annual meeting in Orlando, FL, including studies of clostridium collagenase histolyticum (CCH [XIAFLEX]).
In the lawsuit, the urologist contended the circumcision was properly performed and the patient’s curvature was due to a previously asymptomatic Peyronie’s condition, which was exacerbated after the circumcision procedure.
Erectile dysfunction has been added the U.S. Surgeon General’s list of diseases caused by smoking.
The FDA has approved collagenase clostridium histolyticum (CCH [XIAFLEX]) as the first medication to treat of Peyronie's disease (PD).
Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.